Drug Trial Radar · NCT05955365
Monotherapy With P2Y12 Inhibitors in Patients With Atrial fIbrillation Undergoing Drug-eluting Stent Implantation
Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
3,010
Planned (sponsor's estimate)
Start
Dec 18, 2023
Primary completion
Dec 31, 2027
Study completion Jun 30, 2028
Sponsor
- Lead sponsor
- Insel Gruppe AG, University Hospital BernAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Sahajanand Medical Technologies Limited
- First posted
- Jul 21, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation require treatment with different antithrombotic drugs. Oral anticoagulants are prescribed to reduce the risk of stroke associated with atrial fibrillation. Antiplatelet substances are prescribed after stent implantation to reduce the risk of adverse cardiac events such as myocardial infarction or stent thrombosis. Treatment with antithrombotic medications can cause bleeding complications, particularly when these substances are combined. The currently recommended standard strategy consists of treatment with 3 antithrombotic medications for at least 1 week up to one month, followed by treatment with two of these medications for up to 6-12 months after stent implantation. Thereafter, patients usually receive long-term treatment with only one drug, an anticoagulant. In the monotherapy group of this study, the investigators will investigate a strategy where only one antithrombotic drug will be used at a time. During the first month after stent implantation, the investigators will prescribe an antiplatelet medication, followed by an oral anticoagulant as monotherapy. This strategy might be associated with fewer bleeding complications, while protecting adequately against thrombotic events. In this study the investigators would like to investigate whether treatment with a single antithrombotic drug ("monotherapy strategy") is associated with benefits compared to the currently recommended combination therapy of antithrombotic medications ("standard-of-care strategy").
Conditions
- Percutaneous Coronary Intervention (PCI)
- Atrial Fibrillation (AF)
- Oral Anticoagulation
- P2Y12 Inhibitor
Interventions
P2Y12 inhibitorDrug
The choice of P2Y12 inhibitor is left at investigator's discretion.
AspirinDrug
Aspirin is administered for up to 1 month after PCI at investigator's discretion
DOACDrug
The choice of DOAC is left at investigator's discretion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The number of participants with a major adverse cardiac or cerebral events (MACCE), defined as the composite of death from any cause, myocardial infarction, stroke or non-central nervous system (non-CNS) systemic embolismTime frame: 12 months
- The number of participants with a major or clinically relevant non-major bleeding (MCB), defined according to the International Society of Thrombosis and Haemostasis (ISTH) criteriaTime frame: 12 months
Locations
18 sites in 9 countries. Site status is shown where the registry gives one.
Hartcentrum Hasselt
Hasselt, Belgium · Recruiting
CHU Nîmes
Nîmes, France · Recruiting
Universitätsklinikum Frankfurt/Main
Frankfurt am Main, Germany · Recruiting
Klinikum Friedrichshafen
Friedrichshafen, Germany · Withdrawn
Ospedale Ferrarotto
Catania, Catania CT, Italy · Recruiting
IRCCS Humanitas
Milan, Rozzano, Italy · Recruiting
UMC public
Amsterdam, Netherlands · Recruiting
Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu
Poznan, Poland · Withdrawn
Hospital Universitario Marques de Valdecilla
Santander, Spain · Recruiting
Universitätsspital Basel
Basel, Switzerland · Recruiting
Inselspital, Bern University Hospital, Department of Cardiology
Bern, Switzerland · Recruiting
Hôpitaux Universitaires de Genève
Geneva, Switzerland · Recruiting
HOCH Health Ostschweiz, Kantonsspital St.Gallen
Sankt Gallen, Switzerland · Recruiting
University Hospital Zürich
Zurich, Switzerland · Recruiting
Kantonsspital Baselland Liestal
Liestal, Basel-Landschaft, Switzerland · Recruiting
Kantonsspital Aarau
Aarau, Canton of Aargau, Switzerland · Recruiting
Cardiocentro Ticino Institute
Lugano, Canton Ticino, Switzerland · Recruiting
Imperial College London
London, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.